The chronic and acute postprandial vascular effects of exenatide vs. metformin in abdominally obese patients with impaired glucose tolerance.

Trial Profile

The chronic and acute postprandial vascular effects of exenatide vs. metformin in abdominally obese patients with impaired glucose tolerance.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2013

At a glance

  • Drugs Exenatide (Primary) ; Metformin
  • Indications Glucose intolerance; Obesity
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 12 Jun 2012 Primary endpoint 'Endothelial-function' has not been met according to results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
    • 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
    • 17 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top